Breaking Down Hims & Hers Health: 6 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Six analysts have recently updated their ratings on Hims & Hers Health (NYSE:HIMS), showing a mix of bullish and indifferent stances. The average 12-month price target has increased to $14.5, up 26.09% from the previous $11.50, with a high estimate of $20.00 and a low of $10.00. Analysts from firms including Canaccord Genuity, Guggenheim, Citigroup, Piper Sandler, Truist Securities, and Leerink Partners have adjusted their ratings and price targets, reflecting a positive outlook on the company's performance. Hims & Hers Health, a telehealth platform, has shown notable revenue growth of 47.5% and strong financial metrics such as net margin, ROE, and ROA, outperforming industry averages.
April 10, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Hims & Hers Health has received mixed but generally positive analyst ratings, with an updated average 12-month price target of $14.5, indicating a bullish outlook. The company's strong revenue growth and financial performance metrics are likely contributors to this positive sentiment.
The increase in the average price target to $14.5, up 26.09% from the previous target, along with the company's impressive revenue growth and financial metrics, suggests a positive short-term impact on HIMS's stock price. The mix of bullish and indifferent ratings from analysts, along with significant upgrades in price targets by firms such as Canaccord Genuity and Citigroup, reflect a strong confidence in the company's future performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100